Sex-related susceptibility in coronavirus disease 2019 (COVID-19): Proposed mechanisms
| dc.contributor.author | Aksoyalp, Zinnet Şevval | |
| dc.contributor.author | Nemutlu Samur, Dilara | |
| dc.date.accessioned | 2022-09-22T06:12:42Z | |
| dc.date.available | 2022-09-22T06:12:42Z | |
| dc.date.issued | 2021 | |
| dc.department | ALKÜ, Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | |
| dc.description.abstract | The importance of sex differences is increasingly acknowledged in the incidence and treatment of disease. Accumulating clinical evidence demonstrates that sex differences are noticeable in COVID-19, and the prevalence, severity, and mortality rate of COVID-19 are higher among males than females. Sex-related genetic and hormonal factors and immunological responses may underlie the sex bias in COVID-19 patients. Angiotensinconverting enzyme 2 (ACE2) and transmembrane protease/serine subfamily member 2 (TMPRSS2) are essential proteins involved in the cell entry of SARS-CoV-2. Since ACE2 is encoded on the X-chromosome, a double copy of ACE2 in females may compensate for virus-mediated downregulation of ACE2, and thus ACE2-mediated cellular protection is greater in females. The X chromosome also contains the largest immune-related genes leading females to develop more robust immune responses than males. Toll-like receptor-7 (TLR-7), one of the key players in innate immunity, is linked to sex differences in autoimmunity and vaccine efficacy, and its expression is greater in females. Sex steroids also affect immune cell function. Estrogen contributes to higher CD4+ and CD8+ T cell activation levels, and females have more B cells than males. Sex differences not only affect the severity and progression of the disease, but also alter the efficacy of pharmacological treatment and adverse events related to the drugs/vaccines used against COVID-19. Administration of different drugs/vaccines in different doses or intervals may be useful to eliminate sex differences in efficacy and side/adverse effects. It should be noted that studies should include sex-specific analyses to develop further sex-specific treatments for COVID-19. | |
| dc.identifier.doi | 10.1016/j.ejphar.2021.174548 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12868/1647 | |
| dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0014299921007044?via%3Dihub | |
| dc.identifier.volume | 912 | en_US |
| dc.identifier.wosquality | Q2 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.language.iso | en | |
| dc.relation.ispartof | European Journal of Pharmacology | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | ACE2 | |
| dc.subject | TMPRSS2 | |
| dc.subject | Immune system | |
| dc.subject | Sex hormones | |
| dc.subject | Vaccines | |
| dc.subject | Adverse drug reactions | |
| dc.title | Sex-related susceptibility in coronavirus disease 2019 (COVID-19): Proposed mechanisms | |
| dc.type | Article |
